{"id":1068150,"date":"2021-12-31T01:42:15","date_gmt":"2021-12-31T06:42:15","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/ocugen-partner-bharat-biotech-announces-positive-immunogenicity-and-safety-data-from-covaxin-bbv152-covid-19-candidate-vaccine-in-children-2\/"},"modified":"2024-08-18T11:43:32","modified_gmt":"2024-08-18T15:43:32","slug":"ocugen-partner-bharat-biotech-announces-positive-immunogenicity-and-safety-data-from-covaxin-bbv152-covid-19-candidate-vaccine-in-children-2","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/ocugen-partner-bharat-biotech-announces-positive-immunogenicity-and-safety-data-from-covaxin-bbv152-covid-19-candidate-vaccine-in-children-2.php","title":{"rendered":"Ocugen Partner, Bharat Biotech, Announces Positive Immunogenicity and Safety Data From COVAXIN\u2122 (BBV152), COVID-19 Candidate Vaccine, in Children 2&#8230;"},"content":{"rendered":"<p><![CDATA[MALVERN, Pa., Dec.  30, 2021  (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and vaccines, announced today that its partner, Bharat Biotech, posted results from a Phase 2\/3 trial conducted in India of candidate vaccine, COVAXIN\u2122\u00a0(BBV152), in children, aged 2 \u2013 18 years, demonstrating a robust neutralizing antibody response and favorable safety profile on the pre-print server, medRXiv. Using a two-dose regimen administered 28-days apart, antibody responses in subjects were comparable to adult data from a previous phase 3 study. Those results demonstrated a greater than 93% reduction in severe disease. These pediatric data were the basis of Ocugen\u2019s pediatric Emergency Use Authorization (EUA) submission in the United States for children 2-18 on November 5, 2021.]]><\/p>\n<p>Follow this link:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/news-release\/2021\/12\/30\/2359334\/0\/en\/Ocugen-Partner-Bharat-Biotech-Announces-Positive-Immunogenicity-and-Safety-Data-From-COVAXIN-BBV152-COVID-19-Candidate-Vaccine-in-Children-2-18-YEARS.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"Ocugen Partner, Bharat Biotech, Announces Positive Immunogenicity and Safety Data From COVAXIN\u2122 (BBV152), COVID-19 Candidate Vaccine, in Children 2...\">Ocugen Partner, Bharat Biotech, Announces Positive Immunogenicity and Safety Data From COVAXIN\u2122 (BBV152), COVID-19 Candidate Vaccine, in Children 2...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Follow this link: Ocugen Partner, Bharat Biotech, Announces Positive Immunogenicity and Safety Data From COVAXIN\u2122 (BBV152), COVID-19 Candidate Vaccine, in Children 2... <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/ocugen-partner-bharat-biotech-announces-positive-immunogenicity-and-safety-data-from-covaxin-bbv152-covid-19-candidate-vaccine-in-children-2.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-1068150","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068150"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1068150"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068150\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1068150"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1068150"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1068150"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}